The Experts below are selected from a list of 303 Experts worldwide ranked by ideXlab platform

H.f. Merk - One of the best experts on this subject based on the ideXlab platform.

  • efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment the ecrit study
    Allergy, 2009
    Co-Authors: Hagen Ott, Jochen Sieber, R. Brehler, Alexander Kapp, Ludger Klimek, Oliver Pfaar, Regina Folsterholst, H.f. Merk
    Abstract:

    Background:  Data supporting a Carry-Over Effect with sublingual immunotherapy (SLIT) are scarce. This randomized, double-blind, placebo-controlled study evaluated the efficacy, Carry-Over Effect and safety of grass pollen SLIT using co-seasonal treatment. Methods:  Patients (7.9–64.7 years) with grass pollen allergy received ultra-rush titration with increasing doses (30, 90, 150 and 300 IR) of a 5-grass pollen mixture every 20 min at the start of the pollen seasons, followed by 300 IR daily until the end of the pollen seasons. A baseline season (no SLIT) was followed by three consecutive treatment seasons and one follow-up season. Symptoms, medication and adverse events were documented and specific immunoglobulin (Ig)E and IgG4 measured. Results:  Data were analysed for 183 of the 213 randomized patients. Mean treatment duration varied between seasons (81.8−92.7 days). Combined scores (symptoms and medication) improved progressively across treatment seasons (up to 44.7% improvement for SLIT compared with baseline) and fluctuated between −11.3% and −14.8% for placebo (P < 0.05). Similar changes were observed for symptom scores, with a successive decrease of 39.7% (SLIT) and fluctuations between +13.6% and −1.51% for placebo (P < 0.05). Combined score (P = 0.0508) and symptom score improvements (P = 0.0144) with SLIT continued during follow up. Increases in specific IgG4 observed in the first season were sustained for SLIT vs placebo throughout treatment (P = 0.0001). Titration and daily SLIT were well tolerated. No serious systemic or anaphylactic reactions were reported. Conclusions:  Seasonal SLIT with ultra-rush titration is well tolerated and Effective from the first treatment season onwards. These data indicate a Carry-Over Effect of seasonal SLIT.

  • Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study
    Allergy, 2008
    Co-Authors: Hagen Ott, Jochen Sieber, R. Brehler, Regina Fölster-holst, Alexander Kapp, Ludger Klimek, Oliver Pfaar, H.f. Merk
    Abstract:

    Background:  Data supporting a Carry-Over Effect with sublingual immunotherapy (SLIT) are scarce. This randomized, double-blind, placebo-controlled study evaluated the efficacy, Carry-Over Effect and safety of grass pollen SLIT using co-seasonal treatment. Methods:  Patients (7.9–64.7 years) with grass pollen allergy received ultra-rush titration with increasing doses (30, 90, 150 and 300 IR) of a 5-grass pollen mixture every 20 min at the start of the pollen seasons, followed by 300 IR daily until the end of the pollen seasons. A baseline season (no SLIT) was followed by three consecutive treatment seasons and one follow-up season. Symptoms, medication and adverse events were documented and specific immunoglobulin (Ig)E and IgG4 measured. Results:  Data were analysed for 183 of the 213 randomized patients. Mean treatment duration varied between seasons (81.8−92.7 days). Combined scores (symptoms and medication) improved progressively across treatment seasons (up to 44.7% improvement for SLIT compared with baseline) and fluctuated between −11.3% and −14.8% for placebo (P 

Hagen Ott - One of the best experts on this subject based on the ideXlab platform.

  • efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment the ecrit study
    Allergy, 2009
    Co-Authors: Hagen Ott, Jochen Sieber, R. Brehler, Alexander Kapp, Ludger Klimek, Oliver Pfaar, Regina Folsterholst, H.f. Merk
    Abstract:

    Background:  Data supporting a Carry-Over Effect with sublingual immunotherapy (SLIT) are scarce. This randomized, double-blind, placebo-controlled study evaluated the efficacy, Carry-Over Effect and safety of grass pollen SLIT using co-seasonal treatment. Methods:  Patients (7.9–64.7 years) with grass pollen allergy received ultra-rush titration with increasing doses (30, 90, 150 and 300 IR) of a 5-grass pollen mixture every 20 min at the start of the pollen seasons, followed by 300 IR daily until the end of the pollen seasons. A baseline season (no SLIT) was followed by three consecutive treatment seasons and one follow-up season. Symptoms, medication and adverse events were documented and specific immunoglobulin (Ig)E and IgG4 measured. Results:  Data were analysed for 183 of the 213 randomized patients. Mean treatment duration varied between seasons (81.8−92.7 days). Combined scores (symptoms and medication) improved progressively across treatment seasons (up to 44.7% improvement for SLIT compared with baseline) and fluctuated between −11.3% and −14.8% for placebo (P < 0.05). Similar changes were observed for symptom scores, with a successive decrease of 39.7% (SLIT) and fluctuations between +13.6% and −1.51% for placebo (P < 0.05). Combined score (P = 0.0508) and symptom score improvements (P = 0.0144) with SLIT continued during follow up. Increases in specific IgG4 observed in the first season were sustained for SLIT vs placebo throughout treatment (P = 0.0001). Titration and daily SLIT were well tolerated. No serious systemic or anaphylactic reactions were reported. Conclusions:  Seasonal SLIT with ultra-rush titration is well tolerated and Effective from the first treatment season onwards. These data indicate a Carry-Over Effect of seasonal SLIT.

  • Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study
    Allergy, 2008
    Co-Authors: Hagen Ott, Jochen Sieber, R. Brehler, Regina Fölster-holst, Alexander Kapp, Ludger Klimek, Oliver Pfaar, H.f. Merk
    Abstract:

    Background:  Data supporting a Carry-Over Effect with sublingual immunotherapy (SLIT) are scarce. This randomized, double-blind, placebo-controlled study evaluated the efficacy, Carry-Over Effect and safety of grass pollen SLIT using co-seasonal treatment. Methods:  Patients (7.9–64.7 years) with grass pollen allergy received ultra-rush titration with increasing doses (30, 90, 150 and 300 IR) of a 5-grass pollen mixture every 20 min at the start of the pollen seasons, followed by 300 IR daily until the end of the pollen seasons. A baseline season (no SLIT) was followed by three consecutive treatment seasons and one follow-up season. Symptoms, medication and adverse events were documented and specific immunoglobulin (Ig)E and IgG4 measured. Results:  Data were analysed for 183 of the 213 randomized patients. Mean treatment duration varied between seasons (81.8−92.7 days). Combined scores (symptoms and medication) improved progressively across treatment seasons (up to 44.7% improvement for SLIT compared with baseline) and fluctuated between −11.3% and −14.8% for placebo (P 

Oliver Pfaar - One of the best experts on this subject based on the ideXlab platform.

  • efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment the ecrit study
    Allergy, 2009
    Co-Authors: Hagen Ott, Jochen Sieber, R. Brehler, Alexander Kapp, Ludger Klimek, Oliver Pfaar, Regina Folsterholst, H.f. Merk
    Abstract:

    Background:  Data supporting a Carry-Over Effect with sublingual immunotherapy (SLIT) are scarce. This randomized, double-blind, placebo-controlled study evaluated the efficacy, Carry-Over Effect and safety of grass pollen SLIT using co-seasonal treatment. Methods:  Patients (7.9–64.7 years) with grass pollen allergy received ultra-rush titration with increasing doses (30, 90, 150 and 300 IR) of a 5-grass pollen mixture every 20 min at the start of the pollen seasons, followed by 300 IR daily until the end of the pollen seasons. A baseline season (no SLIT) was followed by three consecutive treatment seasons and one follow-up season. Symptoms, medication and adverse events were documented and specific immunoglobulin (Ig)E and IgG4 measured. Results:  Data were analysed for 183 of the 213 randomized patients. Mean treatment duration varied between seasons (81.8−92.7 days). Combined scores (symptoms and medication) improved progressively across treatment seasons (up to 44.7% improvement for SLIT compared with baseline) and fluctuated between −11.3% and −14.8% for placebo (P < 0.05). Similar changes were observed for symptom scores, with a successive decrease of 39.7% (SLIT) and fluctuations between +13.6% and −1.51% for placebo (P < 0.05). Combined score (P = 0.0508) and symptom score improvements (P = 0.0144) with SLIT continued during follow up. Increases in specific IgG4 observed in the first season were sustained for SLIT vs placebo throughout treatment (P = 0.0001). Titration and daily SLIT were well tolerated. No serious systemic or anaphylactic reactions were reported. Conclusions:  Seasonal SLIT with ultra-rush titration is well tolerated and Effective from the first treatment season onwards. These data indicate a Carry-Over Effect of seasonal SLIT.

  • Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study
    Allergy, 2008
    Co-Authors: Hagen Ott, Jochen Sieber, R. Brehler, Regina Fölster-holst, Alexander Kapp, Ludger Klimek, Oliver Pfaar, H.f. Merk
    Abstract:

    Background:  Data supporting a Carry-Over Effect with sublingual immunotherapy (SLIT) are scarce. This randomized, double-blind, placebo-controlled study evaluated the efficacy, Carry-Over Effect and safety of grass pollen SLIT using co-seasonal treatment. Methods:  Patients (7.9–64.7 years) with grass pollen allergy received ultra-rush titration with increasing doses (30, 90, 150 and 300 IR) of a 5-grass pollen mixture every 20 min at the start of the pollen seasons, followed by 300 IR daily until the end of the pollen seasons. A baseline season (no SLIT) was followed by three consecutive treatment seasons and one follow-up season. Symptoms, medication and adverse events were documented and specific immunoglobulin (Ig)E and IgG4 measured. Results:  Data were analysed for 183 of the 213 randomized patients. Mean treatment duration varied between seasons (81.8−92.7 days). Combined scores (symptoms and medication) improved progressively across treatment seasons (up to 44.7% improvement for SLIT compared with baseline) and fluctuated between −11.3% and −14.8% for placebo (P 

Ludger Klimek - One of the best experts on this subject based on the ideXlab platform.

  • efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment the ecrit study
    Allergy, 2009
    Co-Authors: Hagen Ott, Jochen Sieber, R. Brehler, Alexander Kapp, Ludger Klimek, Oliver Pfaar, Regina Folsterholst, H.f. Merk
    Abstract:

    Background:  Data supporting a Carry-Over Effect with sublingual immunotherapy (SLIT) are scarce. This randomized, double-blind, placebo-controlled study evaluated the efficacy, Carry-Over Effect and safety of grass pollen SLIT using co-seasonal treatment. Methods:  Patients (7.9–64.7 years) with grass pollen allergy received ultra-rush titration with increasing doses (30, 90, 150 and 300 IR) of a 5-grass pollen mixture every 20 min at the start of the pollen seasons, followed by 300 IR daily until the end of the pollen seasons. A baseline season (no SLIT) was followed by three consecutive treatment seasons and one follow-up season. Symptoms, medication and adverse events were documented and specific immunoglobulin (Ig)E and IgG4 measured. Results:  Data were analysed for 183 of the 213 randomized patients. Mean treatment duration varied between seasons (81.8−92.7 days). Combined scores (symptoms and medication) improved progressively across treatment seasons (up to 44.7% improvement for SLIT compared with baseline) and fluctuated between −11.3% and −14.8% for placebo (P < 0.05). Similar changes were observed for symptom scores, with a successive decrease of 39.7% (SLIT) and fluctuations between +13.6% and −1.51% for placebo (P < 0.05). Combined score (P = 0.0508) and symptom score improvements (P = 0.0144) with SLIT continued during follow up. Increases in specific IgG4 observed in the first season were sustained for SLIT vs placebo throughout treatment (P = 0.0001). Titration and daily SLIT were well tolerated. No serious systemic or anaphylactic reactions were reported. Conclusions:  Seasonal SLIT with ultra-rush titration is well tolerated and Effective from the first treatment season onwards. These data indicate a Carry-Over Effect of seasonal SLIT.

  • Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study
    Allergy, 2008
    Co-Authors: Hagen Ott, Jochen Sieber, R. Brehler, Regina Fölster-holst, Alexander Kapp, Ludger Klimek, Oliver Pfaar, H.f. Merk
    Abstract:

    Background:  Data supporting a Carry-Over Effect with sublingual immunotherapy (SLIT) are scarce. This randomized, double-blind, placebo-controlled study evaluated the efficacy, Carry-Over Effect and safety of grass pollen SLIT using co-seasonal treatment. Methods:  Patients (7.9–64.7 years) with grass pollen allergy received ultra-rush titration with increasing doses (30, 90, 150 and 300 IR) of a 5-grass pollen mixture every 20 min at the start of the pollen seasons, followed by 300 IR daily until the end of the pollen seasons. A baseline season (no SLIT) was followed by three consecutive treatment seasons and one follow-up season. Symptoms, medication and adverse events were documented and specific immunoglobulin (Ig)E and IgG4 measured. Results:  Data were analysed for 183 of the 213 randomized patients. Mean treatment duration varied between seasons (81.8−92.7 days). Combined scores (symptoms and medication) improved progressively across treatment seasons (up to 44.7% improvement for SLIT compared with baseline) and fluctuated between −11.3% and −14.8% for placebo (P 

Alexander Kapp - One of the best experts on this subject based on the ideXlab platform.

  • efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment the ecrit study
    Allergy, 2009
    Co-Authors: Hagen Ott, Jochen Sieber, R. Brehler, Alexander Kapp, Ludger Klimek, Oliver Pfaar, Regina Folsterholst, H.f. Merk
    Abstract:

    Background:  Data supporting a Carry-Over Effect with sublingual immunotherapy (SLIT) are scarce. This randomized, double-blind, placebo-controlled study evaluated the efficacy, Carry-Over Effect and safety of grass pollen SLIT using co-seasonal treatment. Methods:  Patients (7.9–64.7 years) with grass pollen allergy received ultra-rush titration with increasing doses (30, 90, 150 and 300 IR) of a 5-grass pollen mixture every 20 min at the start of the pollen seasons, followed by 300 IR daily until the end of the pollen seasons. A baseline season (no SLIT) was followed by three consecutive treatment seasons and one follow-up season. Symptoms, medication and adverse events were documented and specific immunoglobulin (Ig)E and IgG4 measured. Results:  Data were analysed for 183 of the 213 randomized patients. Mean treatment duration varied between seasons (81.8−92.7 days). Combined scores (symptoms and medication) improved progressively across treatment seasons (up to 44.7% improvement for SLIT compared with baseline) and fluctuated between −11.3% and −14.8% for placebo (P < 0.05). Similar changes were observed for symptom scores, with a successive decrease of 39.7% (SLIT) and fluctuations between +13.6% and −1.51% for placebo (P < 0.05). Combined score (P = 0.0508) and symptom score improvements (P = 0.0144) with SLIT continued during follow up. Increases in specific IgG4 observed in the first season were sustained for SLIT vs placebo throughout treatment (P = 0.0001). Titration and daily SLIT were well tolerated. No serious systemic or anaphylactic reactions were reported. Conclusions:  Seasonal SLIT with ultra-rush titration is well tolerated and Effective from the first treatment season onwards. These data indicate a Carry-Over Effect of seasonal SLIT.

  • Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study
    Allergy, 2008
    Co-Authors: Hagen Ott, Jochen Sieber, R. Brehler, Regina Fölster-holst, Alexander Kapp, Ludger Klimek, Oliver Pfaar, H.f. Merk
    Abstract:

    Background:  Data supporting a Carry-Over Effect with sublingual immunotherapy (SLIT) are scarce. This randomized, double-blind, placebo-controlled study evaluated the efficacy, Carry-Over Effect and safety of grass pollen SLIT using co-seasonal treatment. Methods:  Patients (7.9–64.7 years) with grass pollen allergy received ultra-rush titration with increasing doses (30, 90, 150 and 300 IR) of a 5-grass pollen mixture every 20 min at the start of the pollen seasons, followed by 300 IR daily until the end of the pollen seasons. A baseline season (no SLIT) was followed by three consecutive treatment seasons and one follow-up season. Symptoms, medication and adverse events were documented and specific immunoglobulin (Ig)E and IgG4 measured. Results:  Data were analysed for 183 of the 213 randomized patients. Mean treatment duration varied between seasons (81.8−92.7 days). Combined scores (symptoms and medication) improved progressively across treatment seasons (up to 44.7% improvement for SLIT compared with baseline) and fluctuated between −11.3% and −14.8% for placebo (P